Mercedes Corina Becerra, Sc.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis, Multidrug-Resistant | 50 | 2020 | 874 | 6.600 |
Why?
|
Antitubercular Agents | 45 | 2022 | 1296 | 3.960 |
Why?
|
Tuberculosis | 32 | 2022 | 1809 | 3.430 |
Why?
|
Peru | 43 | 2022 | 845 | 2.290 |
Why?
|
Tuberculosis, Pulmonary | 19 | 2022 | 817 | 2.280 |
Why?
|
Mycobacterium tuberculosis | 29 | 2022 | 1811 | 2.150 |
Why?
|
Contact Tracing | 12 | 2020 | 262 | 2.110 |
Why?
|
Isoniazid | 13 | 2022 | 260 | 2.000 |
Why?
|
Family Characteristics | 12 | 2020 | 940 | 1.220 |
Why?
|
Drug Resistance, Multiple, Bacterial | 9 | 2016 | 592 | 0.900 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 3 | 2013 | 90 | 0.860 |
Why?
|
Directly Observed Therapy | 6 | 2012 | 141 | 0.780 |
Why?
|
Sputum | 11 | 2021 | 467 | 0.670 |
Why?
|
Rifampin | 6 | 2021 | 310 | 0.530 |
Why?
|
Tuberculosis, Meningeal | 1 | 2014 | 42 | 0.520 |
Why?
|
Medication Systems, Hospital | 1 | 2013 | 161 | 0.440 |
Why?
|
Latent Tuberculosis | 3 | 2021 | 198 | 0.400 |
Why?
|
Child, Preschool | 29 | 2022 | 41184 | 0.390 |
Why?
|
Remote Consultation | 1 | 2013 | 246 | 0.380 |
Why?
|
Microbial Sensitivity Tests | 7 | 2019 | 1910 | 0.370 |
Why?
|
Adolescent | 37 | 2022 | 85064 | 0.370 |
Why?
|
Pyrazinamide | 3 | 2016 | 55 | 0.350 |
Why?
|
Infant | 23 | 2022 | 34561 | 0.350 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2033 | 0.340 |
Why?
|
Child | 35 | 2022 | 74418 | 0.340 |
Why?
|
Family Health | 1 | 2013 | 1289 | 0.340 |
Why?
|
Mass Screening | 6 | 2022 | 5218 | 0.330 |
Why?
|
Antibiotics, Antitubercular | 3 | 2005 | 105 | 0.320 |
Why?
|
Developing Countries | 8 | 2013 | 2727 | 0.290 |
Why?
|
Treatment Failure | 6 | 2016 | 2686 | 0.290 |
Why?
|
Electronic Health Records | 2 | 2013 | 4275 | 0.280 |
Why?
|
Humans | 88 | 2022 | 715636 | 0.260 |
Why?
|
National Health Programs | 4 | 2021 | 447 | 0.250 |
Why?
|
Tuberculin Test | 3 | 2019 | 219 | 0.250 |
Why?
|
Pakistan | 4 | 2022 | 291 | 0.240 |
Why?
|
Primary Prevention | 2 | 2020 | 1162 | 0.230 |
Why?
|
DNA-Directed RNA Polymerases | 1 | 2005 | 369 | 0.230 |
Why?
|
Population Surveillance | 3 | 2011 | 2652 | 0.220 |
Why?
|
Age Factors | 12 | 2022 | 18774 | 0.220 |
Why?
|
Ethambutol | 2 | 2016 | 61 | 0.210 |
Why?
|
Adult | 42 | 2022 | 212228 | 0.210 |
Why?
|
Drug Resistance, Multiple | 2 | 2001 | 264 | 0.210 |
Why?
|
Young Adult | 16 | 2022 | 56137 | 0.200 |
Why?
|
Treatment Outcome | 21 | 2022 | 62037 | 0.200 |
Why?
|
Cost of Illness | 1 | 2010 | 1842 | 0.200 |
Why?
|
Female | 50 | 2022 | 377052 | 0.200 |
Why?
|
HIV Infections | 7 | 2020 | 15905 | 0.190 |
Why?
|
Infant, Newborn | 10 | 2022 | 24779 | 0.190 |
Why?
|
Male | 48 | 2022 | 350156 | 0.190 |
Why?
|
Internet | 1 | 2012 | 3071 | 0.190 |
Why?
|
Retrospective Studies | 25 | 2021 | 72439 | 0.190 |
Why?
|
Early Diagnosis | 2 | 2015 | 1195 | 0.190 |
Why?
|
Endemic Diseases | 1 | 2000 | 160 | 0.180 |
Why?
|
Secondary Prevention | 3 | 2016 | 1511 | 0.180 |
Why?
|
Economics | 1 | 2000 | 147 | 0.180 |
Why?
|
Environmental Exposure | 1 | 2013 | 4054 | 0.170 |
Why?
|
Incidence | 8 | 2019 | 20761 | 0.160 |
Why?
|
Communicable Disease Control | 3 | 2021 | 813 | 0.160 |
Why?
|
Health Services Accessibility | 5 | 2022 | 5032 | 0.160 |
Why?
|
Prevalence | 8 | 2020 | 14878 | 0.160 |
Why?
|
BCG Vaccine | 3 | 2014 | 357 | 0.160 |
Why?
|
Prospective Studies | 10 | 2021 | 51355 | 0.140 |
Why?
|
Lost to Follow-Up | 1 | 2016 | 101 | 0.140 |
Why?
|
Amidohydrolases | 1 | 2016 | 178 | 0.140 |
Why?
|
Drug Therapy, Combination | 7 | 2021 | 6572 | 0.130 |
Why?
|
Blastocystis Infections | 1 | 2013 | 7 | 0.130 |
Why?
|
Entamoebiasis | 1 | 2013 | 12 | 0.130 |
Why?
|
Giardiasis | 1 | 2013 | 21 | 0.130 |
Why?
|
Protozoan Infections | 1 | 2013 | 40 | 0.130 |
Why?
|
Amebiasis | 1 | 2013 | 34 | 0.130 |
Why?
|
Cohort Studies | 12 | 2020 | 40042 | 0.120 |
Why?
|
Genotype | 4 | 2019 | 12931 | 0.120 |
Why?
|
Disease Progression | 2 | 2019 | 13219 | 0.110 |
Why?
|
Delivery of Health Care | 2 | 2021 | 4884 | 0.110 |
Why?
|
Drug Resistance, Bacterial | 3 | 2013 | 1100 | 0.110 |
Why?
|
Haiti | 2 | 2013 | 541 | 0.110 |
Why?
|
Sentinel Surveillance | 1 | 2014 | 301 | 0.110 |
Why?
|
Middle Aged | 20 | 2022 | 214618 | 0.110 |
Why?
|
Health Policy | 2 | 2017 | 2650 | 0.110 |
Why?
|
Disease Notification | 1 | 2012 | 96 | 0.110 |
Why?
|
Electronic Prescribing | 1 | 2013 | 120 | 0.110 |
Why?
|
Comprehensive Health Care | 1 | 2012 | 128 | 0.100 |
Why?
|
Public-Private Sector Partnerships | 1 | 2012 | 127 | 0.100 |
Why?
|
Urban Health Services | 1 | 2012 | 183 | 0.100 |
Why?
|
Likelihood Functions | 1 | 2014 | 1004 | 0.100 |
Why?
|
Computer Systems | 1 | 2012 | 479 | 0.100 |
Why?
|
Analysis of Variance | 3 | 2020 | 6500 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6726 | 0.100 |
Why?
|
Mutation | 4 | 2016 | 29270 | 0.100 |
Why?
|
Professional Competence | 1 | 2014 | 452 | 0.100 |
Why?
|
Socioeconomic Factors | 3 | 2022 | 7736 | 0.100 |
Why?
|
Geographic Information Systems | 1 | 2012 | 265 | 0.100 |
Why?
|
Information Systems | 1 | 2012 | 390 | 0.100 |
Why?
|
Disease Outbreaks | 1 | 2000 | 1742 | 0.100 |
Why?
|
Community Health Services | 3 | 2011 | 658 | 0.090 |
Why?
|
Registries | 2 | 2013 | 8042 | 0.090 |
Why?
|
Time Factors | 8 | 2014 | 40892 | 0.090 |
Why?
|
Follow-Up Studies | 6 | 2019 | 39334 | 0.090 |
Why?
|
Epidemiologic Studies | 1 | 2012 | 652 | 0.090 |
Why?
|
Public Health | 1 | 2022 | 2430 | 0.090 |
Why?
|
Program Development | 2 | 2012 | 1333 | 0.090 |
Why?
|
Lesotho | 3 | 2013 | 55 | 0.080 |
Why?
|
Tobacco Smoke Pollution | 1 | 2014 | 816 | 0.080 |
Why?
|
Health Personnel | 3 | 2021 | 3045 | 0.080 |
Why?
|
Risk | 3 | 2016 | 9812 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2022 | 3027 | 0.080 |
Why?
|
Russia | 3 | 2014 | 388 | 0.080 |
Why?
|
Community-Acquired Infections | 1 | 2011 | 474 | 0.080 |
Why?
|
HIV Seronegativity | 1 | 2008 | 207 | 0.080 |
Why?
|
Models, Organizational | 1 | 2011 | 583 | 0.080 |
Why?
|
Genes, Bacterial | 1 | 2011 | 1132 | 0.080 |
Why?
|
HIV Seropositivity | 1 | 2012 | 924 | 0.080 |
Why?
|
Odds Ratio | 5 | 2022 | 9977 | 0.080 |
Why?
|
Cross Infection | 1 | 2015 | 1405 | 0.070 |
Why?
|
Salvage Therapy | 1 | 2013 | 1307 | 0.070 |
Why?
|
Risk Factors | 12 | 2022 | 70927 | 0.070 |
Why?
|
World Health Organization | 3 | 2020 | 1287 | 0.070 |
Why?
|
Recurrence | 3 | 2016 | 8238 | 0.070 |
Why?
|
Clinical Protocols | 4 | 2021 | 1474 | 0.070 |
Why?
|
Program Evaluation | 2 | 2011 | 2538 | 0.070 |
Why?
|
Checklist | 1 | 2012 | 790 | 0.070 |
Why?
|
Health Education | 1 | 2012 | 1067 | 0.070 |
Why?
|
Aged | 10 | 2021 | 162383 | 0.070 |
Why?
|
Treatment Refusal | 1 | 2008 | 420 | 0.070 |
Why?
|
Streptomycin | 1 | 2004 | 72 | 0.070 |
Why?
|
Drug Resistance, Microbial | 2 | 2005 | 885 | 0.060 |
Why?
|
Drug Administration Schedule | 4 | 2016 | 5034 | 0.060 |
Why?
|
Infection Control | 1 | 2010 | 953 | 0.060 |
Why?
|
Tuberculin | 1 | 2022 | 75 | 0.060 |
Why?
|
Case-Control Studies | 4 | 2015 | 21802 | 0.060 |
Why?
|
Health Services Needs and Demand | 1 | 2011 | 1442 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2011 | 960 | 0.060 |
Why?
|
Public Health Administration | 1 | 2005 | 242 | 0.060 |
Why?
|
Community Health Centers | 1 | 2005 | 435 | 0.050 |
Why?
|
Feeding Behavior | 1 | 2014 | 3193 | 0.050 |
Why?
|
Tajikistan | 1 | 2000 | 5 | 0.050 |
Why?
|
X-Rays | 1 | 2021 | 294 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 3946 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2011 | 7445 | 0.050 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 12495 | 0.050 |
Why?
|
Sequence Analysis, DNA | 2 | 2016 | 4910 | 0.050 |
Why?
|
Ambulatory Care | 2 | 2008 | 2766 | 0.040 |
Why?
|
Pregnancy | 1 | 2020 | 27366 | 0.040 |
Why?
|
Vulnerable Populations | 2 | 2017 | 660 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 7982 | 0.040 |
Why?
|
Methicillin Resistance | 1 | 1999 | 203 | 0.040 |
Why?
|
Substance-Related Disorders | 2 | 2012 | 4182 | 0.040 |
Why?
|
Sampling Studies | 1 | 2000 | 639 | 0.040 |
Why?
|
Social Support | 1 | 2008 | 2119 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15899 | 0.040 |
Why?
|
Decision Making | 1 | 2011 | 3844 | 0.040 |
Why?
|
Smoking | 1 | 2014 | 8950 | 0.040 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 2019 | 494 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8886 | 0.040 |
Why?
|
International Cooperation | 1 | 2003 | 1441 | 0.040 |
Why?
|
Prognosis | 1 | 2016 | 28987 | 0.030 |
Why?
|
Research Design | 2 | 2013 | 5913 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3543 | 0.030 |
Why?
|
Health Resources | 1 | 2001 | 929 | 0.030 |
Why?
|
Gene Expression | 2 | 2019 | 7950 | 0.030 |
Why?
|
Endolimax | 1 | 2013 | 6 | 0.030 |
Why?
|
Entamoeba | 1 | 2013 | 6 | 0.030 |
Why?
|
Blastocystis hominis | 1 | 2013 | 6 | 0.030 |
Why?
|
Giardia lamblia | 1 | 2013 | 17 | 0.030 |
Why?
|
Genetic Fitness | 1 | 2015 | 115 | 0.030 |
Why?
|
Sex Factors | 2 | 2020 | 10660 | 0.030 |
Why?
|
Cost-Benefit Analysis | 3 | 2021 | 5269 | 0.030 |
Why?
|
Capreomycin | 1 | 2013 | 13 | 0.030 |
Why?
|
HIV | 1 | 2001 | 1542 | 0.030 |
Why?
|
Amoxicillin-Potassium Clavulanate Combination | 1 | 2013 | 25 | 0.030 |
Why?
|
Risk Assessment | 4 | 2020 | 23482 | 0.030 |
Why?
|
Kanamycin | 1 | 2013 | 64 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14887 | 0.030 |
Why?
|
Clarithromycin | 1 | 2013 | 79 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2014 | 528 | 0.030 |
Why?
|
Biological Assay | 1 | 2016 | 648 | 0.030 |
Why?
|
Latvia | 1 | 2012 | 14 | 0.030 |
Why?
|
Molecular Epidemiology | 1 | 2015 | 483 | 0.030 |
Why?
|
Logistic Models | 2 | 2022 | 13606 | 0.030 |
Why?
|
Estonia | 1 | 2012 | 57 | 0.030 |
Why?
|
Philippines | 1 | 2012 | 86 | 0.030 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2001 | 1905 | 0.030 |
Why?
|
HIV Seroprevalence | 1 | 2012 | 87 | 0.030 |
Why?
|
Georgia (Republic) | 1 | 2011 | 42 | 0.030 |
Why?
|
England | 1 | 2013 | 517 | 0.030 |
Why?
|
Fluoroquinolones | 1 | 2013 | 306 | 0.030 |
Why?
|
Radiography | 1 | 2022 | 6975 | 0.030 |
Why?
|
Focus Groups | 1 | 2015 | 1263 | 0.030 |
Why?
|
Drug Therapy | 1 | 2014 | 517 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2003 | 3683 | 0.020 |
Why?
|
Models, Theoretical | 2 | 2014 | 3584 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2021 | 1460 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2014 | 12490 | 0.020 |
Why?
|
Monocytes | 1 | 2019 | 2627 | 0.020 |
Why?
|
Health Surveys | 1 | 2000 | 4030 | 0.020 |
Why?
|
Genetic Loci | 1 | 2019 | 2613 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2011 | 431 | 0.020 |
Why?
|
Financing, Personal | 1 | 2011 | 311 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2015 | 2593 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2582 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2995 | 0.020 |
Why?
|
Consensus | 1 | 2015 | 2744 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2012 | 884 | 0.020 |
Why?
|
Survival Rate | 1 | 2000 | 13210 | 0.020 |
Why?
|
Education | 1 | 2008 | 543 | 0.020 |
Why?
|
Retreatment | 1 | 2006 | 623 | 0.020 |
Why?
|
Peroxidases | 1 | 2004 | 145 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2016 | 3898 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2011 | 1554 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2014 | 58288 | 0.010 |
Why?
|
Motivation | 1 | 2012 | 1897 | 0.010 |
Why?
|
Parents | 1 | 2015 | 3175 | 0.010 |
Why?
|
Oxidoreductases | 1 | 2004 | 426 | 0.010 |
Why?
|
Algorithms | 2 | 2012 | 13765 | 0.010 |
Why?
|
Survival Analysis | 1 | 2014 | 10513 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2016 | 13635 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 11956 | 0.010 |
Why?
|
Virulence | 1 | 2004 | 1338 | 0.010 |
Why?
|
Patient Care Team | 1 | 2011 | 2582 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2012 | 3453 | 0.010 |
Why?
|
Models, Statistical | 1 | 2014 | 5091 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2012 | 2941 | 0.010 |
Why?
|
Poverty | 2 | 2001 | 2605 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2493 | 0.010 |
Why?
|
Databases, Factual | 1 | 2013 | 7901 | 0.010 |
Why?
|
Health Care Costs | 1 | 2011 | 3165 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2004 | 2954 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10429 | 0.010 |
Why?
|
Health Planning | 1 | 1998 | 243 | 0.010 |
Why?
|
HIV-1 | 1 | 2013 | 6899 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15184 | 0.010 |
Why?
|
Morals | 1 | 1998 | 268 | 0.010 |
Why?
|
Body Mass Index | 1 | 2012 | 12546 | 0.010 |
Why?
|
Patient Compliance | 1 | 2004 | 2745 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 11194 | 0.010 |
Why?
|
Rural Population | 1 | 2001 | 2175 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2011 | 23383 | 0.010 |
Why?
|
Bacterial Proteins | 1 | 2004 | 3939 | 0.010 |
Why?
|
Mental Disorders | 1 | 2008 | 6445 | 0.010 |
Why?
|
Disease Management | 1 | 1999 | 2519 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2001 | 4133 | 0.000 |
Why?
|